These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21338542)

  • 1. Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach.
    Antonanzas F; Juarez-Castello C; Rodriguez-Ibeas R
    Health Econ Policy Law; 2011 Jul; 6(3):391-403. PubMed ID: 21338542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Innovative agreements with the pharmaceutical industry: "pay for performance"].
    Badia X; Prior M
    Farm Hosp; 2010; 34(2):53-5. PubMed ID: 20207566
    [No Abstract]   [Full Text] [Related]  

  • 5. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.
    Zaric GS; O'brien BJ
    Health Econ; 2005 Aug; 14(8):793-803. PubMed ID: 15685669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managed care risk contracts and substance abuse treatment.
    Sturm R
    Inquiry; 2000; 37(2):219-25. PubMed ID: 10985114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits.
    Zaric GS; Xie B
    Value Health; 2009; 12(5):838-45. PubMed ID: 19490563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with independent pharmacy owners' satisfaction with Medicare Part D contracts.
    Zhang S; Doucette WR; Urmie JM; Xie Y; Brooks JM
    Res Social Adm Pharm; 2010 Jun; 6(2):121-9. PubMed ID: 20511111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicaid managed care reimbursement for HIV and its implications for access to care.
    Conviser R; Murray M; Lau D
    Am J Manag Care; 2000 Sep; 6(9):990-9. PubMed ID: 11184069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical policy in Italy: towards a structural change?
    Ghislandi S; Krulichova I; Garattini L
    Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Health insurance discount contracts: problems and risks for the general practitioner in the medical care of patients with chronic illness].
    Leutgeb R; Mahler C; Laux G; Weschnetz A; Szecsenyi J
    Dtsch Med Wochenschr; 2009 Jan; 134(5):181-6. PubMed ID: 19180404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].
    Hammerman A; Greenberg D
    Harefuah; 2012 Jun; 151(6):364-7, 376. PubMed ID: 22991869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value-Based Pharmaceutical Contracts: Value for Whom?
    Kannarkat JT; Good CB; Parekh N
    Value Health; 2020 Feb; 23(2):154-156. PubMed ID: 32113619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An ethical perspective on health care insurance reform.
    Brennan TA
    Am J Law Med; 1993; 19(1-2):37-74. PubMed ID: 8368202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survey offers wealth of medical practice cost data.
    Capitation Rates Data; 1998 Feb; 3(2):19-22. PubMed ID: 10345853
    [No Abstract]   [Full Text] [Related]  

  • 16. A changing paradigm in the study and adoption of emerging health care technologies: coverage with evidence development.
    Wallner PE; Konski A
    J Am Coll Radiol; 2008 Nov; 5(11):1125-9. PubMed ID: 18954812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods of providing prescription drug benefits in health plans.
    Curtiss FR
    Am J Hosp Pharm; 1986 Oct; 43(10):2428-35. PubMed ID: 3788994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The why and how about risk contracts.
    Jackson RJ; Wolff TM
    Mich Med; 2008; 107(6):30-1. PubMed ID: 19055303
    [No Abstract]   [Full Text] [Related]  

  • 19. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
    Sneed RC; May WL; Stencel C
    Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Regional differences in the use of 'no substitution' in the elderly after introduction of rebate contracts].
    Hoffmann F; Windt R; Glaeske G
    Gesundheitswesen; 2011 Jul; 73(7):438-42. PubMed ID: 20544592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.